Rigontec GmbH raises $5.3 mln in Series A

Rigontec GmbH said Tuesday it raised 4.8 million Euros (about US$5.3 mln) in a second closing of a series A round from Forbion Capital Partners and Sunstone Capital. Rigontec said total Series A funding was 14.25 million Euros (US$15.7 mln). Bonn, Germany-based Rigontech is a biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

112 Views

Forbion Capital sells PneumRx

Forbion Capital Partners has sold PneumRx to BTG. Cash consideration was $230 million and up to $245 million in performance related future milestone payments.PneumRx is a interventional pulmonology business that makes and distributes the RePneu Coil System, which aims to treat advanced emphysema.

Exosome Diagnostics nabs $27 mln

Exosome Diagnostics said Tuesday that it has closed $27 million in Series B financing. New investors QIAGEN and Arcus Ventures led the round with participation from Tiger Partners, CD Ventures, Monashee Capital, NGN Capital and Forbion Capital Partners. Leerink Swann served as financial advisor and placement agent to Exosome on the transaction. In conjunction with the funding, Dr. Steven Soignet, general partner at Arcus Ventures, has been added to Exosome’s board of directors. Exosome is a developer of molecular diagnostic tests.

RuiYi and arGEN-X Announce License Agreement

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

Astley-Sparke Joins Forbion Capital

Philip Astley-Sparke has joined Forbion Capital Partners as a venture partner based in Boston. He had been BioVex’s president and CEO since 2005. Once Amgen acquired BioVex in March 2011, Astley-Sparke served as VP and GM of Amgen until the following December. PRESS RELEASE Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO […]

Promedior Appoints President and CEO

Promedior, a clinical stage biotechnology company developing biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn as president and chief executive officer. In March, the company announced the closing of a Series D financing round led by Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare […]

Promedior Raises $21.5 Million

Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This […]

Promedior Inks $21.5M

Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round.  New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round […]

arGEN-X Inks $37M Series B

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

CircuLite Raises $30m for Series D

CircuLite, a developer of a surgically implanted blood pump for long-term use in heart failure patients, has raised $30 million for its oversubscribed Series D financing round. The round was led by new investor, MacAndrews & Forbes Holdings, and Netherlands-based Forbion Capital Partners, a founding VC of CircuLite and the largest investor in the company. […]

Oxyrane Adds $26.5M

Oxyrane UK Ltd., a biopharmaceutical company based in The Netherlands, has closed on $26.5 million in a equity round of funding. Investors include Forbion Capital Partners, Morningside Groups and New Science Ventures. Sander Slootweg of Forbion and Gerald Chan of Morningside Group have joined the company’s board. Oxyrane is developing enzyme replacement therapies to treat rare inheritied diseases.

AM-Pharma Raises $40M Series D

AM-Pharma NV, a Dutch developer of Alkaline Phosphatase for treatment of severe inflammatory diseases, has closed on 29.2 million euro ($39.8 million) in a Series D financing round led by Ysios Capital Partners. Kurma Life Science Partners co-led the round, which included participation from the venture arms of two global Healthcare companies, Abbott and Shire. Venture funds BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital also joined in the round.

Amakem Seals $25.3M Series A

Forbion Capital Partners has led an 18 million euro ($25.3 million) Series A round for Belgium-based Amakem NV. Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners also contributed to the round. Amakem will use the money to expand its ophthalmology drug development portfolio, the company said.

Bluebird Bio Closes $30M Venture Round

Cambridge, Mass.-based Bluebird Bio, which is developing gene therapies for genetic disorders, has inked $30 million in fresh capital from investors including ARCH Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group. ARCH Venture Partners was a new investor in the company, and the firm’s managing director Steven Gillis will join Bluebird Bio’s board. The company completed a $35 million Series B in early 2010.

2 Comments

Cellnovo Raises $48.4M Series B

London-based Cellnovo, which develops a mobile diabetes management system, has raised £30 million ($48.4 million) in a Series B financing round led by Paris-based Edmond de Rothschild Investment Partners. Forbion Capital Partners, Auriga Partners, NBGI Ventures and Credit Agricole Private Equity also participated, as did Series A investors Advent Venture Partners, HealthCare Ventures and NESTA.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget